OBJECTIVE: The aim of this study was to investigate local regional control, survival, and morbidity in patients with FIGO IIB and IIIB squamous cell carcinoma of the cervix treated with primary extended field (prophylactic paraaoratic radiation) radiation and weekly cisplatin. METHODS: Sixty-seven patients (44 IIB and 23 IIIB) with carcinoma of the cervix received cisplatin at 1 mg/kg (up to 60 mg) weekly and extended field radiation therapy including the paraaortic nodes and brachytherapy. RESULTS: After the scheduled therapy 94.1% of the patients were complete responders. Seventy-five percent are alive without evidence of disease with a mean follow-up of 47.5 months. CONCLUSION: This study confirms the ability to give concomitant weekly cisplatin and prophylactic paraaortic radiation with minimal morbidity. The encouraging Kaplan-Meier survival of 75% and only eight pelvic failures warrants further investigation. Copyright 1997 Academic Press.
OBJECTIVE: The aim of this study was to investigate local regional control, survival, and morbidity in patients with FIGO IIB and IIIB squamous cell carcinoma of the cervix treated with primary extended field (prophylactic paraaoratic radiation) radiation and weekly cisplatin. METHODS: Sixty-seven patients (44 IIB and 23 IIIB) with carcinoma of the cervix received cisplatin at 1 mg/kg (up to 60 mg) weekly and extended field radiation therapy including the paraaortic nodes and brachytherapy. RESULTS: After the scheduled therapy 94.1% of the patients were complete responders. Seventy-five percent are alive without evidence of disease with a mean follow-up of 47.5 months. CONCLUSION: This study confirms the ability to give concomitant weekly cisplatin and prophylactic paraaortic radiation with minimal morbidity. The encouraging Kaplan-Meier survival of 75% and only eight pelvic failures warrants further investigation. Copyright 1997 Academic Press.
Authors: Seung Gyu Park; Jin Hee Kim; Young Kee Oh; Sang Jun Byun; Mi Young Kim; Sang Hoon Kwon; Ok Bae Kim Journal: Cancer Res Treat Date: 2014-07-21 Impact factor: 4.679
Authors: Mushabbab Al Asiri; Mutahir A Tunio; Reham Mohamed; Yasser Bayoumi; Abdulrehman Alhadab; Rasha M Saleh; Muhannad Saud AlArifi; Abdelaziz Alobaid Journal: Cancer Manag Res Date: 2014-09-09 Impact factor: 3.989
Authors: Francis Adumata Asamoah; Joel Yarney; Aba Scott; Verna Vanderpuye; Zhigang Yuan; Daniel C Fernandez; Michael E Montejo; Mervin Agyeman; Samuel Ntiamoah Boateng; Kwabena Anarfi; Charles Aidoo; Mian M Shahzad; Jing-Yi Chern; Hye-Sook Chon; Robert M Wenham; Kosj Yamoah; Kamran A Ahmed Journal: JCO Glob Oncol Date: 2020-10